1. Gianni L et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 2016; 17(6):791-800. Artikel bei PubMed
2. Schneeweiss A et al. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 2018; 89: 27-35.
Artikel bei PubMed
3. Untch M et al. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 2011; 29: 3351-3357. Artikel bei PubMed
4. Untch M et al. Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44) J Clinc Oncol 2018; 36: 1308-1316. Artikel bei PubMed
5. Jackisch C et al. Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial. JAMA Oncol 2019 May 1;5(5):e190339. doi:10.1001/jamaoncol.2019.0339. Artikel bei PubMed
6. Cortazar P et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384: 164-172. Artikel bei PubMed
7. von Minckwitz G et al. Trastuzumab Emtansine for residual invasive HER2- positive breast cancer. NEJM 2019, 380: 617-62. Artikel bei PubMed
8. Verma S et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012; 367 (19): 1783-91. Artikel bei PubMed
9. Krop IE et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol 2017. 18(6):743-754. Artikel bei PubMed
10. Jackisch C et al. SABCS 2015, Poster P4-13-28.
11. AGO Breast Committee. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Recommendations 2020. www.ago-online.de
12. Giordano SH et al. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update. JCO 2018; 36(26): 2736-2740.
Artikel bei PubMed
13. S3-Leitlinie Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms
September 2020; AWMF-Registernr: 032-045OL.